- The Wall Street Journal•23 minutes ago
Bayer and U.S. healthcare investor Versant Ventures plan to establish a stem-cell research company called BlueRock Therapeutics, with initial joint funding of $225 million.
- Motley Fool•10 hours ago
Inovio had a setback with its cervical dysplasia vaccine program, but the biotech also had a huge win this year.
- Insider Monkey•11 hours ago
The European Medicines Agency (EMA) has recently accepted to review the Marketing Authorization Application (MAA) of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (ADR) (NYSE:SNY) for Dupixent (dupilumab) as a treatment for adult moderate-to-severe atopic dermatitis (AD) patients who are systemic therapy candidates. Dupixent is an investigational biologic therapy that inhibits the signaling of two […]
SAN.PA : Summary for SANOFI - Yahoo Finance
Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
|Bid||71.12 x 1000|
|Ask||71.74 x 44000|
|Day's Range||75.28 - 76.95|
|52 Week Range||62.50 - 80.90|
|PE Ratio (TTM)||23.42|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|